Pancreatic beta-cell Imaging

胰腺β细胞成像

• 批准号: 6585786
• 负责人: MANSSUR YALPANI
• 金额: $ 40万
• 依托单位: CARBOMER, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-08-10 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6585786
• 关键词: bioimaging /biomedical imaging; cell line; cell transplantation; diabetes mellitus; drug design /synthesis /production; drug receptors; fluorescence microscopy; fluorine; magnetic resonance imaging; magnetism; pancreatic islets; reagent /indicator; sulfonylurea

DESCRIPTION (provided by applicant): Diabetes affects some 20 million people in the U.S. The World Health Organization expects the global diabetics population to rise from 130 million to 350 million by 2025. Diabetes therapy based on transplanted islets or insulin-secreting Beta cells offers substantial advantages over conventional treatments. We plan to develop Magnetic Resonance Imaging (MRI) probes for in vivo non-invasive monitoring of the disposition, mass and viability of transplanted insulin secreting tissue. The availability of quantitative in vivo MRI methods for islet and Beta-cell mass would provide benefits for early diagnosis of the disease and for islet transplantation research aimed at improving current protocols methodologies. It would also establish islet transplantation as a realistic treatment option for patients requiring insulin replacement therapy. Our plan is to evaluate the feasibility of using novel Beta-cell specific MRI probes to monitor in vivo the disposition, mass and viability of large volumes of transplanted islets or Beta-cells. The new probes will be based on MRI imagable probes that display specificity towards membrane components of pancreatic Beta cell mass. The initial phase will establish the in vitro feasibility of the new diagnostic probes, leading up to subsequent in vivo studies. The development of imaging techniques and reagents that lead to non-invasive in vivo assessment of Beta-cell mass may have a significant impact in managing pancreas and/or islet transplantation, in the understanding of the pathogenesis in islet engraftment, and for assessing the efficacy of modulations in type 1 diabetes therapy.

描述(申请人提供)：美国约有2000万人患有糖尿病。世界卫生组织预计，到2025年，全球糖尿病人口将从1.3亿增加到3.5亿。基于移植的胰岛或分泌胰岛素的Beta细胞的糖尿病疗法比传统疗法具有实质性的优势。我们计划开发磁共振成像(MRI)探针，用于体内非侵入性监测移植的胰岛素分泌组织的处置、质量和活性。胰岛和β细胞团块的体内定量MRI方法的可用性将为疾病的早期诊断和旨在改进现有方案方法学的胰岛移植研究提供有利条件。它还将使胰岛移植成为需要胰岛素替代疗法的患者的一种现实的治疗选择。我们的计划是评估使用新型的Beta细胞特异性MRI探针在体内监测大量移植的胰岛或Beta细胞的处置、质量和活性的可行性。新的探针将基于MRI成像的探针，显示对胰腺Beta细胞团的膜成分的特异性。最初阶段将确定新诊断探针的体外可行性，从而导致后续的体内研究。无创活体评估β细胞质量的成像技术和试剂的发展可能对胰腺和/或胰岛移植的管理、对胰岛植入的发病机制的理解以及对1型糖尿病治疗的调节效果的评估有重要影响。